研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]Peking Union Medical College Hospital Beijing, Beijing, China, 100730[3]Chongqing University Cancer Hospital Chongqing, Chongqing, China, 400000[4]The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing, China, 400000[5]Fujian Cancer Hospital Fuzhou, Fujian, China, 350000[6]Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060[7]The First Affiliated Hospital Sun Yat-Sen University Guangzhou, Guangdong, China, 510080[8]Yuebei People's Hospital Shaoguan, Guangdong, China, 512025[9]Affiliated Hospital of Guangdong Medical University Zhangjiang, Guangdong, China, 524000[10]The Fifth Affiliated Hospital Sun Yat-Sen University Zhuhai, Guangdong, China, 519000[11]Guangxi Medical University Affiliated Tumor Hospital Nanning, Guangxi, China, 530200[12]The Fourth Hospital of Hebei medical University Shijiazhuang, Hebei, China, 050019河北医科大学第四医院[13]Anyang Cancer Hospital Anyang, Henang, China, 455000[14]Henan Cancer Hospital Zhengzhou, Henan, China, 450008[15]Hubei Cancer Hospital Wuhan, Hubei, China, 430079[16]Hunan Cancer Hospital Changsha, Hunan, China, 410006[17]Xiangya Hospital Central South University Changsha, Hunan, China, 410008[18]The Third Xiangya Hospital of Central South University Changsha, Hunan, China, 410013[19]Huaian First People's Hospital Huai'an, Jiangsu, China, 223300[20]Jiangsu Cancer Hospital Nanjing, Jiangsu, China, 210029[21]Jiangsu People's Hospital Nanjing, Jiangsu, China, 210029[22]The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China, 330012[23]Qilu Hospital of Shandong University Jinan, Shandong, China, 250012[24]Baoji Central Hospital Baoji, Shanxi, China, 721008[25]Shanxi Cancer Hospital Taiyuan, Shanxi, China, 030000[26]Xijing Hospital of Airforce Medical University Xi'an, Shanxi, China, 710000[27]First Affiliated Hospital of Xi'anjiantong University Xi'an, Shanxi, China, 710061[28]Tianjin Cancer Hospital Tianjin, Tianjin, China, 300060[29]The first Hospital of Zhengjiang Province Hangzhou, Zhejiang, China, 310000[30]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China, 310005[31]Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China, 310006[32]Zhejiang Hospital Hangzhou, Zhejiang, China, 310013[33]Zhejiang People's Hospital Hangzhou, Zhejiang, China, 310014[34]Ningbo Medical Center Lihuili Hospital Ningbo, Zhejiang, China, 315000[35]Taizhou Hospital of Zhejiang Province Taizhou, Zhejiang, China, 317000[36]Taizhou Central Hospital Taizhou, Zhejiang, China, 318000[37]Anhui Chest Hospital Hefei, Anhui, China, 230000
研究目的：
This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as consolidation treatment in subjects with locally advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.
